Filing Flows › GoodRx Holdings (GDRX) › Capital expenditures
GoodRx Holdings (GDRX) capital expenditures by quarter
GoodRx Holdings' capital expenditures were $362K in Q2 2026 (second quarter 2026), -68% from Q1 2026. Over the last 7 quarters it ranged from $142K (Q1 2025) to $1.7M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $362K | -68% | -7% |
| Q1 2026 | $1.1M | -8% | +700% |
| Q4 2025 | $1.2M | -29% | +666% |
| Q3 2025 | $1.7M | +348% | — |
| Q2 2025 | $390K | +175% | — |
| Q1 2025 | $142K | -12% | — |
| Q4 2024 | $162K | — | — |
Q2 2026 at a glance
GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%, net earnings $8.5M, operating cash flow $80.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is GoodRx Holdings' capital expenditures?
GoodRx Holdings' capital expenditures were $362K in Q2 2026 (second quarter 2026), -68% from Q1 2026.
How has GoodRx Holdings' capital expenditures changed?
Over the last 7 quarters it ranged from $142K (Q1 2025) to $1.7M (Q3 2025).